Correspondence 0001193125-25-067061 from ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC.
Date: March 28, 2025 · CIK: 0001426800 · Accession: 0001193125-25-067061
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285970
Letter
Re: Assembly Biosciences, Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285970 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Assembly Biosciences, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-285970) (the “Registration Statement”) to 4:30 p.m. Eastern Time on Tuesday, April 1, 2025 or as soon thereafter as practicable. The Company acknowledges that both the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff of the U.S. Securities and Exchange Commission. Please contact P. Michelle Gasaway of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at +1.213.687.5122, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
March 28, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Regards,
By:
Show Raw Text
CORRESP 1 filename1.htm CORRESP March 28, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Assembly Biosciences, Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285970 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Assembly Biosciences, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-285970) (the “Registration Statement”) to 4:30 p.m. Eastern Time on Tuesday, April 1, 2025 or as soon thereafter as practicable. The Company acknowledges that both the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff of the U.S. Securities and Exchange Commission. Please contact P. Michelle Gasaway of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at +1.213.687.5122, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter. Regards, By: /s/ Jason A. Okazaki Name: Jason A. Okazaki Title: Chief Executive Officer and President cc: P. Michelle Gasaway Skadden, Arps, Slate, Meagher & Flom LLP John O. Gunderson Assembly Biosciences, Inc. Two Tower Place, 7 th Floor, South San Francisco, CA 94080